M. Brann

发表

Human dopamine D1 receptor encoded by an intronless gene on chromosome 5

R. Rozmahel, J. Kennedy, R. Sunahara, 1990, Nature.

Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies

D. Price, A. Levey, M. Brann, 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Dopamine D2 receptor dimers and receptor-blocking peptides.

P. Seeman, M. Brann, B. O'dowd, 1996, Biochemical and biophysical research communications.

Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains.

M. Brann, T. Spalding, E. Burstein, 1996, Biochemical pharmacology.

Site‐directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding.

J. Wess, M. Brann, D. Gdula, 1991, The EMBO journal.

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

A. Levey, H. Meltzer, U. Hacksell, 2004, Psychopharmacology.

Expression of a cloned muscarinic receptor in A9 L cells.

T. Bonner, M. Brann, N. Buckley, 1987, Molecular pharmacology.

Phosphorylation and Palmitoylation of the Human D2L Dopamine Receptor in Sf9 Cells

M. Caron, M. Brann, B. O'dowd, 1994, Journal of neurochemistry.

Identification of a small intracellular region of the muscarinic m3 receptor as a determinant of selective coupling to PI turnover

J. Wess, T. Bonner, M. Brann, 1989, FEBS letters.

Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor.

D. Weiner, M. Brann, J. L. Hansen, 2004, Molecular pharmacology.

Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation

M. Brann, T. Spalding, Jian-Nong Ma, 2006, Molecular Pharmacology.

Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes.

M. Brann, K. Robbins, J. Gutkind, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Diurnal expression of transducin mRNA and translocation of transducin in rods of rat retina.

M. Brann, L. Cohen, 1987, Science.

Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist

U. Hacksell, D. Weiner, M. Brann, 2004, Journal of Pharmacology and Experimental Therapeutics.

Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins.

M. Brann, T. Spalding, E. Burstein, 1997, Molecular pharmacology.

Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

U. Hacksell, D. Weiner, M. Brann, 2002, Journal of medicinal chemistry.

In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists

R. Leurs, U. Hacksell, D. Weiner, 2007, Journal of Pharmacology and Experimental Therapeutics.

Muscarinic receptors transform NIH 3T3 cells through a Ras-dependent signalling pathway inhibited by the Ras-GTPase-activating protein SH3 domain

M. Brann, I. Macara, A. Sorisky, 1994, Molecular and cellular biology.

Cell-Based Assays for G-Protein-Coupled/Tyrosine Kinase-Coupled Receptors

M. Brann, D. Lannigan, C. Dorman, 1996 .

Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor

D. Weiner, M. Brann, N. Nash, 2002, Neuropharmacology.

Constitutive activation of muscarinic receptors by the G‐protein Gq

M. Brann, T. Spalding, E. Burstein, 1995, FEBS letters.

Structural basis of the subtype selectivity of muscarinic antagonists: a study with chimeric m2/m5 muscarinic receptors.

J. Wess, M. Brann, D. Gdula, 1992, Molecular pharmacology.

Serotonin-S2 and dopamine-D2 receptors are the same size in membranes.

M. Brann, 1985, Biochemical and biophysical research communications.

Expression of GTP-binding proteins and prostaglandin E2 receptors during human T cell activation.

M. Brann, B. Howard, W. Holter, 1991, Cellular immunology.

Constitutively Active Mutants of the Histamine H1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

L. Pardo, K. Sansuk, R. Leurs, 2008, Molecular Pharmacology.

Functional Importance of the Ala116–Pro136 Region in the Calcium-sensing Receptor

M. Brann, P. O'Hara, P. Krogsgaard‐Larsen, 2000, The Journal of Biological Chemistry.

Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6.

J. W. Wells, M. Brann, T. Spalding, 1997, Biochemistry.

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.

C. Halldin, L. Farde, U. Hacksell, 2008, The international journal of neuropsychopharmacology.

Pharmacological and behavioral profile of ACP-103, a novel 5-HT 2A receptor inverse agonist

Robert I. Davis, M. Geyer, D. Weiner, 2006 .

Amino Acid Side Chains That Define Muscarinic Receptor/G-protein Coupling

M. Brann, T. Spalding, E. Burstein, 1996, The Journal of Biological Chemistry.

Structure-Function of Muscarinic Receptor Coupling to G Proteins

M. Brann, D. Hill-Eubanks, T. Spalding, 1995, The Journal of Biological Chemistry.

Identification of the Atypical L-Type Ca2+ Channel Blocker Diltiazem and Its Metabolites As Ghrelin Receptor Agonists

M. Brann, N. Nash, E. Currier, 2007, Molecular Pharmacology.

as Ghrelin receptor agonists

M. Brann, N. Nash, E. Currier, 2007 .

Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells.

C. Heilman, M. Brann, S. V. Jones, 1991, Molecular pharmacology.

Localization and quantitation of opsin and transducin mRNAs in bovine retina by in situ hybridization histochemistry

M. Brann, W. Young, 1986, FEBS letters.

Chimeric m2/m3 muscarinic receptors: role of carboxyl terminal receptor domains in selectivity of ligand binding and coupling to phosphoinositide hydrolysis.

J. Wess, T. Bonner, M. Brann, 1990, Molecular pharmacology.

The striatum and cerebral cortex express different muscarinic receptor mRNAs

T. Bonner, M. Brann, N. Buckley, 1988, FEBS letters.

Discovery of novel peptide/receptor interactions: identification of PHM-27 as a potent agonist of the human calcitonin receptor.

M. Brann, N. Nash, E. Currier, 2004, Biochemical pharmacology.

Structure/function relationships of a G-protein coupling pocket formed by the third intracellular loop of the m5 muscarinic receptor.

M. Brann, T. Spalding, E. Burstein, 1998, Biochemistry.

Interactions of Muscarinic Receptors with the Heterotrimeric G Proteins Gq and G12: Transduction of Proliferative Signals

B. Conklin, M. Brann, H. Bräuner‐Osborne, 1997, Journal of neurochemistry.

High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells.

M. Brann, C. Dorman, T. Messier, 1995, Pharmacology & toxicology.

Pharmacological Characterization of AC-90179: a Selective 5-HT 2A Receptor Inverse Agonist

U. Hacksell, D. Weiner, M. Brann, 2004 .

Signal transduction by guanine nucleotide-binding proteins.

M. Brann, W. Simonds, A. Spiegel, 1988, Recent progress in hormone research.

Detection of multiple forms of Giα in HL60 cells

M. Brann, P. Gierschik, H. Malech, 1987 .

Identification of a family of muscarinic acetylcholine receptor genes.

T. Bonner, M. Brann, A. Young, 1987, Science.

The Second Intracellular Loop of the m5 Muscarinic Receptor Is the Switch Which Enables G-protein Coupling*

M. Brann, T. Spalding, E. Burstein, 1998, The Journal of Biological Chemistry.

Transforming G protein-coupled receptors transduce potent mitogenic signals in NIH 3T3 cells independent on cAMP inhibition or conventional protein kinase C.

M. Brann, J. Gutkind, G. Kalinec, 1993, Oncogene.

Stimulation of arachidonic acid release and inhibition of mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells.

B. Conklin, T. Bonner, M. Brann, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.

T. Bonner, M. Brann, N. Buckley, 1989, Molecular pharmacology.

Inositol trisphosphate mediates cloned muscarinic receptor‐activated conductances in transfected mouse fibroblast A9 L cells.

M. Goodman, J. Barker, M. Brann, 1990, The Journal of physiology.

Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.

T. Bonner, W. Young, M. Brann, 1986, Proceedings of the National Academy of Sciences of the United States of America.

(±)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-methyl-5-aryl-2-penten-4-ynyl) oximes: Potent muscarinic agonists

M. Brann, T. Mirzadegan, J. Jaén, 1995 .

In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.

M. Brann, S. Barrett, J. Jaén, 1995, Life sciences.

Muscarinic acetylcholine receptor subtypes: localization and structure/function.

M. Brann, D. Hill-Eubanks, J. Ellis, 1993, Progress in brain research.

Localization of a family of muscarinic receptor mRNAs in rat brain

M. Brann, T. Bonner, N. Buckley, 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues.

A. Levey, M. Brann, F. Dörje, 1991, Molecular pharmacology.

Antagonist binding profiles of five cloned human muscarinic receptor subtypes.

J. Wess, M. Brann, F. Dörje, 1991, The Journal of pharmacology and experimental therapeutics.

Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes.

M. Brann, J. Ellis, J. Huyler, 1991, Biochemical pharmacology.

Selectivity profile of the novel muscarinic antagonist UH‐AH 37 determined by the use of cloned receptors and isolated tissue preparations

J. Wess, M. Brann, F. Dörje, 1991, British journal of pharmacology.

Molecular biology of G-protein-coupled receptors.

M. Brann, 1992 .

6 The Dopamine D 1 Receptors

R. Sunahara, P. Seeman, H. Niznik, 1992 .

The Dopamine D1 Receptors

Philip Seeman, Mark R. Brann, P. Seeman, 1992 .

Characterization of the Mas‐related gene family: structural and functional conservation of human and rhesus MrgX receptors

M. Brann, N. Nash, E. Burstein, 2006, British journal of pharmacology.

Discovery of an ectopic activation site on the M(1) muscarinic receptor.

U. Hacksell, M. Brann, E. Currier, 2002, Molecular pharmacology.

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.

M A Geyer, M. Geyer, K. Krebs-Thomson, 2001, The Journal of pharmacology and experimental therapeutics.

Identification of a Ligand-dependent Switch within a Muscarinic Receptor*

M. Brann, T. Spalding, E. Burstein, 1998, The Journal of Biological Chemistry.

Functional partial agonism at cloned human muscarinic acetylcholine receptors.

M. Brann, P. Krogsgaard‐Larsen, E. Falch, 1996, European journal of pharmacology.

Structure of a G-protein-coupling Domain of a Muscarinic Receptor Predicted by Random Saturation Mutagenesis (*)

M. Brann, D. Hill-Eubanks, H. Bräuner‐Osborne, 1996, The Journal of Biological Chemistry.

Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells.

M. Brann, H. Bräuner‐Osborne, 1996, European journal of pharmacology.

Studies of the Pharmacology, Localization, and Structure of Muscarinic Acetylcholine Receptors a

M. Brann, D. Hill-Eubanks, T. Spalding, 1993, Annals of the New York Academy of Sciences.

Structure/function relationships of muscarinic acetylcholine receptors.

J Ellis, M. Brann, V. Klimkowski, 1993, Life sciences.

Bacterial expression of human muscarinic receptor fusion proteins and generation of subtype‐specific antisera

A. Levey, M. Brann, Tom M. Stormann, 1990, FEBS letters.

Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia.

A. Levey, D. Weiner, M. Brann, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Membrane attachment of recombinant G-protein α-subunits in excess of βγ subunits in a eukaryotic expression system

M. Brann, W. Simonds, A. Spiegel, 1989 .

The distribution of a dopamine D2 receptor mRNA in rat brain

D. Weiner, M. Brann, 1989, FEBS letters.

Localization of mRNAs encoding the α‐subunits of signal‐transducing G‐proteins within rat brain and among peripheral tissues

M. Brann, R. Collins, A. Spiegel, 1987, FEBS letters.

Pharmacology of polymorphic variants of the human 5-HT1A receptor.

U. Hacksell, D. Weiner, M. Brann, 2004, Biochemical pharmacology.

Monitoring Interactions between Receptor Tyrosine Kinases and Their Downstream Effector Proteins in Living Cells Using Bioluminescence Resonance Energy Transfer

M. Brann, F. Piu, N. Nash, 2007, Molecular Pharmacology.

Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer

D. Weiner, M. Brann, F. Piu, 2007, Molecular Pharmacology.

Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family.

N. Schork, P. Insel, D. Weiner, 2003, Genomics.

Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers.

J. Wess, T. Bonner, M. Brann, 1990, Molecular pharmacology.

Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.

D L Price, D. Price, S. Hersch, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis.

M. Brann, D. Hill-Eubanks, T. Spalding, 1995, The Journal of pharmacology and experimental therapeutics.

D1 and D2 dopamine receptor mRNA in rat brain.

A. Levey, R. Sunahara, P. Seeman, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Myristoylation of an inhibitory GTP-binding protein alpha subunit is essential for its membrane attachment.

M. Brann, W. Simonds, T. L. Jones, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist

U. Hacksell, E. Pham, D. Weiner, 2005, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Ethan S. Burstein, Fabrice Piu, Mark R. Brann, 2006, Journal of Pharmacology and Experimental Therapeutics.

A serotonin receptor gene (5HT1A) variant found in a Tourette's syndrome patient.

D. Comings, M. Brann, B. O'dowd, 1996, Biochemical and biophysical research communications.

Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout.

D. Weiner, M. Brann, F. Piu, 2006, Current pharmaceutical design.

8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist.

O. Zuiderveld, R. Leurs, U. Hacksell, 2004, Molecular pharmacology.

Microiontophoretic injection of fluorescent tracer combined with simultaneous immunofluorescent histochemistry for the demonstration of efferents from the caudate-putamen projecting to the globus pallidus

P. Emson, M. Brann, 1980, Neuroscience Letters.

M. Brann, J. Gutkind, E. Currier, 1998, Oncogene.

Identification of novel selective V2 receptor non-peptide agonists.

M. Brann, F. Piu, J. Lameh, 2008, Biochemical pharmacology.

Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist.

M. Brann, F. Piu, J. Donello, 2008, European journal of pharmacology.

Electrophysiological characterization of cloned m1 muscarinic receptors expressed in A9 L cells.

T. Bonner, J. Barker, M. Brann, 1988, Proceedings of the National Academy of Sciences of the United States of America.

D 1 and D 2 dopamine receptor mRNA in rat brain ( striatum / substantia nigra / amygdala / septum / in situ hybridization )

A. Levey, R. Sunahara, P. Seeman, 2022 .

Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.

U. Hacksell, M. Brann, F. Piu, 2005, Journal of medicinal chemistry.

Functional importance of the Ala(116)-Pro(136) region in the calcium-sensing receptor. Constitutive activity and inverse agonism in a family C G-protein-coupled receptor.

M. Brann, P. Krogsgaard‐Larsen, H. Bräuner‐Osborne, 2000, The Journal of biological chemistry.

Identification of novel subtype selective RAR agonists.

U. Hacksell, M. Brann, F. Piu, 2005, Biochemical pharmacology.

Dopamine receptors are located on rods in bovine retina

W. Young, M. Brann, 1986, Neuroscience Letters.

Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist.

M. Brann, S. Barrett, H. Tecle, 1998, Journal of medicinal chemistry.

Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H(3) receptor.

D. Weiner, M. Brann, N. Nash, 2002, Neuropharmacology.

Dopamine receptors on photoreceptor membranes couple to a GTP-binding protein which is sensitive to both pertussis and cholera toxin.

M. Brann, C. Jelsema, 1985, Biochemical and biophysical research communications.

The use of [3H](-)-DO 710 as selective dopaminergic ligand for binding and autoradiographic studies.

M. Martres, M. Bouthenet, N. Salès, 1985, European journal of pharmacology.

ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models

U. Hacksell, M. Brann, D. Bonhaus, 2007, Journal of Pharmacology and Experimental Therapeutics.

Turning induced by unilateral injection of antimicrotubular agents into the substantia nigra

M. Brann, R. Lenox, J. Ellis, 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist.

M. Brann, F. Piu, R. Olsson, 2008, European journal of pharmacology.

Molecular cloning and expression of a dopamine D2 receptor from human retina.

D. Weiner, T. Stormann, M. Brann, 1990, Molecular pharmacology.

Exploring the potential for subtype-selective muscarinic agonists in glaucoma.

M. Brann, T. Spalding, E. Woldemussie, 2001, Life sciences.

Chemical genomics: massively parallel technologies for rapid lead identification and target validation

Uli Hacksell, Norman Nash, Ethan S. Burstein, 2004, Cytotechnology.

Cloned muscarinic receptor subtypes expressed in A9 L cells differ in their coupling to electrical responses.

T. Bonner, J. Barker, M. Brann, 1988, Molecular Pharmacology.

Functional Screening of Drug Target Genes

A. Levey, D. Weiner, M. Brann, 2004 .

3H-(-)DO 710 discriminates guanine nucleotide sensitive and insensitive dopamine binding sites

M. Martres, P. Sokoloff, J. Schwartz, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions.

M. Brann, J. Ellis, M. Seidenberg, 1993, Molecular pharmacology.